Gene Therapy 2002: A New Start

  • N. H. Mulder
Conference paper
Part of the Developments in Hematology and Immunology book series (DIHI, volume 38)

Abstract

Following the turbulent end of the twentieth century when one protocol violation led to a most regrettable toxic death threatening clinical gene therapy in its very existence, it was hoped that easier navigation would lie ahead. Complications arising in the initial successful study of X-linked combined immune deficiency negate this hope. In this review we will produce some evidence for a promise of chances of success on a clinical level in the foreseeable future.

Keywords

Gene Therapy Thymidine Kinase Glucose Dependent Insulinotropic Polypeptide Suicide Gene Suicide Gene Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Habib NA, Sarraf CE, Mitry RR et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 211;12:219–26.Google Scholar
  2. 2.
    Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968–76.PubMedGoogle Scholar
  3. 3.
    Morsy MA, Caskey CT. Expanded-capacity adenoviral vectors — the helper-dependent vectors. Mol Med Today 1999;5:18–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Dmitriev I, Kashentseva E, Rogers BE et al. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000;74:6875–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorge-nesis in long-term rodent studies of rAAV vectors. Gene Ther 2001;8:1343–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Miyoshi H, Smith KA, Mosier DE et al. Transduction of human CD34+ cells that mediate long term engraftment of NOD/SCID mice by HIV vectors. Science 1999;283:5402.CrossRefGoogle Scholar
  7. 7.
    Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of trans-fection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther 2002;9:372–380.PubMedCrossRefGoogle Scholar
  8. 8.
    Hanna E, Zhang X, Woodlis J, Breau R, Suen J, Li S. Intramuscular electro-poration delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther 2001;8:151–57.PubMedCrossRefGoogle Scholar
  9. 9.
    Li S, Huang L. Non viral gene therapy: promises and challenges. Gene Ther 2000;7:31–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Xiao X, Li J, Samulski R. Efficient long term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996;70:8098–108.PubMedGoogle Scholar
  11. 11.
    Pang S, Dannull J, Kaboo R et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997;57:495–99.PubMedGoogle Scholar
  12. 12.
    Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-IL specific gene therapy. Gene Ther 2000;7:493–98.PubMedCrossRefGoogle Scholar
  13. 13.
    Cheung AT, Dayanandan B, Lewis JT, et al. Glucose-dependent insulin release from genetically engineered K cells. Science 2000;290:1959–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11:2389–401.PubMedCrossRefGoogle Scholar
  15. 15.
    Herman JR, Adler HL, Aquilar-Cordova E, Rojas-Martinex A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999;10:1239–49.PubMedCrossRefGoogle Scholar
  16. 16.
    Merritt JA, Roth JA, Logothesis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies. Semin Oncol 2001;28:105–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Phillips MI. Gene therapy for hypertension: the preclinical data. Methods Enzymol 2002;346:3–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Baumgartner I, Isner JM. Somatic gene therapy in the cardiovascular system. Annu Rev Physiol 2001;63:427–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002;6:127–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Flotte TR, Laube BL. Gene therapy in cystic fibrosis. Chest 2001;120:124S-31S.PubMedCrossRefGoogle Scholar
  21. 21.
    Manno CS, Glader B, Ragni MV, et al. A phase I trial of AAV-mediated muscle directed gene transfer for hemophilia B. Thromb Haemost 2001;86: OC2488.Google Scholar
  22. 22.
    Roth DA, Tawa NE, O’Brien JM, Treco DA, Seiden RF. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia. N Engl J Med 2001;344:1735–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • N. H. Mulder
    • 1
  1. 1.Dept. of Medical OncologyUniversity Hospital GroningenGroningenThe Netherlands

Personalised recommendations